A highly effective clinical protocol that combines the #immunotherapy atezolizumab (Tecentriq®) with standard adjuvant FOLFOX chemotherapy to treat patients with resected stage III #colon #cancer exhibiting deficient DNA mismatch repair (dMMR).
#Oncology #Immunology #sflorg
https://www.sflorg.com/2026/03/ongy03272601.html